This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation
Expertise
Specializes in:
Tourism & Travel
Also works in:
Government / Politics
Poetry & Literature
Journalism
History
Cinema, Film, TV, Drama
Education / Pedagogy
Computers (general)
Law (general)
IT (Information Technology)
More
Less
Rates
Blue Board entries made by this user
0 entries
Portfolio
Sample translations submitted: 1
French to English: Editorial du Monde (French newspaper): Justice et Santé WORD
Source text - French
Editorial
Justice et santé
Article paru dans l'édition du 26.09.09
ang contaminé, hormone de croissance, amiante : comme toutes les grandes affaires de santé publique qui, d'une manière ou d'une autre, ont fini par arriver devant la justice ces dernières années, celle du Distilbène est aussi longue que douloureuse.
Dans les années 1950, 1960 et 1970, cet oestrogène de synthèse a été prescrit à des millions de femmes enceintes dans le monde pour prévenir des fausses couches. Dès 1953, une étude américaine émettait des doutes sur l'innocuité de ce produit, mais ce n'est qu'en 1971 qu'il fut déclaré contre-indiqué aux Etats-Unis, et en 1977 qu'il fut interdit en France. Beaucoup trop tard pour éviter de terribles « dégâts » : malformations gynécologiques, stérilité et cancers pour les filles de ces femmes traitées au Distilbène, atteintes de l'appareil uro-génital, plus rarement, chez les garçons. L'on estime que 160 000 personnes ont été exposées à ce médicament en France.
Quelque 150 d'entre elles ont engagé, depuis des années, une bataille judiciaire pour tenter d'obtenir réparation. Mais elles se heurtaient, le plus souvent, à la quasi-impossibilité de fournir les preuves (en l'occurrence les ordonnances médicales de leurs mères) que leur réclamaient les deux laboratoires pharmaceutiques mis en cause.
Il faut donc saluer la décision de principe très importante qu'a prise la Cour de cassation jeudi 24 septembre. Les « filles Distilbène » n'auront plus à prouver la marque du médicament prescrit à leur mère ; ce sont les laboratoires (UCB Pharma et Novartis) qui devront prouver que leur médicament n'est pas en cause. Restera toutefois aux victimes à démontrer, expertises à l'appui, que leur cancer a bien été provoqué par le Distilbène.
Cette inversion de la charge de la preuve principale, dans les affaires de santé publique, n'est pas tout à fait inédite : elle confirme la reconnaissance croissante des victimes, déjà constatée dans l'affaire du sang contaminé par le VIH et dans celle de l'amiante. Peu à peu, le fossé jusque-là infranchissable entre la justice et les victimes commence donc à se combler. Même si la lenteur et la complexité des procédures peuvent sembler désespérantes, le monde médical, pharmaceutique ou médico-administratif n'apparaît plus totalement à l'abri de condamnations civiles, voire pénales. Cela suppose, évidemment, la connaissance du risque par ceux qui l'ont fait courir à d'autres, sans laquelle il ne saurait y avoir d'intentionnalité du délit. L'arrêt de la Cour ne permettra pas d'effacer la douleur, mais, on l'espère, un terrible déni de justice.
Translation - English Health and Justice
LE MONDE | 25.09.09 | 14h18
Contaminated blood, growth hormones, asbestos: as with all large public health issues which, in one way or another, have ended up in court lately, the Diethylstilbestrol (DES) affair is as long as it is painful.
In the fifties, sixties and seventies, this synthetic estrogen was prescribed to millions of pregnant women around the world to prevent miscarriages. In 1953, an American study raised doubt as to the harmlessness of the drug, but it wasn’t until 1971 that it was declared contraindicated in the United States, and in 1977 it was banned in France. Much too late to avoid terrible “damage”: gynecological deformities, sterility and cancer in girls and women treated with DES, stricken in the urogenital region, and, more rarely, in boys. It is estimated that 16,000 people have been exposed to this drug in France.
Some 150 of them have, for many years, taken up a legal battle to try and receive reparations. But, more often than not, they came up against the quasi-impossibility of providing evidence (it happened to be the medical prescriptions of their mothers) required by the two pharmaceutical companies implicated.
We must, therefore, salute the very important provisional decision made by the Court of cassation on Thursday, September 24. The “DES girls” no longer have to produce the brand of medicine prescribed to their mother; it is now the companies (UCB Pharma and Novartis) who must prove that their drug is not involved. It is still up to the victims to show that their cancer was caused by DES.
This reversal of requirement of principal evidence, in public health issues, is not completely new: it confirms the victims’ acknowledgement, already contested in the blood contaminated by HIV and asbestos. Little by little, the huge gap between justice and victims is beginning to narrow. Even if the slowness and complexity of the procedures seem hopeless, the medical, pharmaceutical and medico-administrative world is not totally protected from civil, even penal, convictions. This supposes, of course, knowledge of risk on the part of those who ran the risk of others, without which there would be no criminal intentionality. The Court’s ruling does not erase the pain, but, hopefully, it will erase a horrible miscarriage of justice.
More
Less
Translation education
Master's degree - Middlebury College in Paris
Experience
Years of experience: 26. Registered at ProZ.com: Dec 2008.
Adobe Acrobat, Adobe Photoshop, Microsoft Excel, Microsoft Office Pro, Microsoft Word, Powerpoint
CV/Resume
CV available upon request
Bio
My very first professional translation assignment was back in 1983, at the age of 18, when I flew off to Oyonnax, France and worked for the summer in the office of the Export Division of Grosfillex, Inc. Inspired by my stay, the next summer I attended the French School at Middlebury College in Vermont and went on to become a French major at Connecticut College, where I founded a French-language newspaper and was awarded the French Department Prize for Outstanding Achievement. In between, I moved briefly to Paris and worked at the L’Oeil Ecoute bookstore in Montparnasse. As a Connecticut College student, I also spent six months in France, studying writing and literature at Université de Paris – Denis Diderot. After a year of working as a reporter in New York, I began the Middlebury College master’s program in Paris. I studied French and Francophone literature at Université de Paris – Nanterre. Concurrently, I held a teaching assistantship at l’ESIT (Ecole Supérieure d’Interprètes et Traducteurs) where I aided French translation students in perfecting their written and spoken English, while learning valuable “tricks of the trade.” I then became a candidate for an M.A. in French Studies, concentrating on the social sciences of France and Francophone regions, such as anthropology, history, government and philosophy, at the Institute of French Studies of New York University. Subsequent to my studies at NYU, I entered the field of teaching. For the next ten+ years, I held French instructor or adjunct professor positions at Tower Hill School (Delaware), Cristina School District (Delaware), Georgetown University (DC), American University (DC), George Mason University (VA), Villanova University (PA), Middlebury-Monterey Language Academy (VT). During this time, I began freelance translating for various authors and companies (see CV). While continuing my freelance endeavors, in 2005, I joined Berlitz Language Center in Washington, DC and became not only a French instructor but also a Manager of Instruction, responsible for hiring the Center’s teaching staff. In 2009, I left Berlitz to focus on my translating business, called “C’est à dire…”, full time. Based in Washington, DC, I currently translate film, academic texts, legal and IT documents, journalistic articles, international development documents, film publicity, and more. I would most warmly welcome the opportunity to translate works of fiction.
Keywords: French, academic texts, film, literary, government
This profile has received 7 visits in the last month, from a total of 4 visitors